Synergistic antitumor activity of vincristine and VP-16-213
- 1 October 1984
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 13 (3) , 176-180
- https://doi.org/10.1007/bf00269024
Abstract
The potential interaction of the antitumor agents vincristine and VP-16-213 was investigated in vivo. DBA/2 mice were inoculated with 106 P388 murine leukemia cells, after which single IP injections of saline only, vincristine only, VP-16-213 only, or a combination of vincristine and VP-16-213 were administered. Long-term survival (> 60 days) was observed in 0/45, 1/45 (2%), 9/135 (7%), and 44/135 (33%) mice, respectively (P<0.001). Treatment was most effective when VP-16-213 was administered 0–72 h after vincristine. A similar trend was observed in mice bearing P1534 murine leukemia. These data demonstrate synergistic antitumor activity between vincristine and VP-16-213 in a murine model.Keywords
This publication has 5 references indexed in Scilit:
- VP-16-213 (etoposide): The mandrake root from Issyk-KulThe American Journal of Medicine, 1982
- In vitro systems for evaluation of combination chemotherapyPharmacology & Therapeutics, 1980
- Effect of VM-26 on the haematological responses of mice to L1210 leukaemiaBritish Journal of Cancer, 1980
- Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 LeukemiaPublished by Elsevier ,1976
- SOME PHARMACOLOGIC PROPERTIES OF VINCRISTINE1965